444912-51-0

(R)-AM1241 binds to cannabinoid (CB) receptors and has greater than 100-fold selectivity for the CB₂ over the CB₁ receptor (K_is = 15 and 5,000 nM, respectively, in a membrane assay using human receptors). (R)-AM1241 acts as an agonist at human CB₂ receptors (EC₅₀ = 118 nM) but an inverse agonist at rat and mouse CB₂ receptors (EC₅₀s = 315 and 341 nM, respectively). Similar to the racemate AM1241 , (R)-AM1241 produces antinociception to thermal, but not mechanical, pain in rats. The pain-reducing effect of (R)-AM1241 is blocked by the CB₂-specific inhibitor SR 144528 but not by either the CB₁-selective inhibitor rimonabant or the opioid receptor blocker naloxone ( | ISO60191).

(R)-AM1241 binds to cannabinoid (CB) receptors and has greater than 100-fold selectivity for the CB2 over the CB1 receptor. Synthetic cannabinoid.Synthetic Cannabinoids

Store at -20°C

[1] B BINGHAM. Species-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomers[J]. British Journal of Pharmacology, 2009, 151 7: 1137. DOI: 10.1038/sj.bjp.0707378
[2] ELIZABETH J RAHN. Antinociceptive effects of racemic AM1241 and its chirally synthesized enantiomers: lack of dependence upon opioid receptor activation.[J]. AAPS Journal, 2010, 12 2: 147-157. DOI: 10.1208/s12248-009-9170-8
[3] MARJOLEIN SOETHOUDT. Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity.[J]. ACS Combinatorial Science, 2017: 13958. DOI: 10.1038/ncomms13958